Form 4: Mirum Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, was granted stock options and restricted stock units on January 21, 2025.

Summary

• Joanne Quan, Chief Medical Officer of Mirum Pharmaceuticals, was granted 40,000 stock options and 10,000 restricted stock units on January 21, 2025.
• The stock options have an exercise price of $47.98 and vest over a period of four years, with 1/4th vesting one year after the Vesting Commencement Date and the remainder vesting monthly over the following three years.
• The restricted stock units vest over three years, with 1/3rd vesting on each anniversary of the Vesting Commencement Date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This type of equity grant is a common practice for incentivizing executives in the pharmaceutical industry.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotech and pharmaceutical industries.
• Vesting schedules are typically structured to encourage long-term performance and retention, similar to those seen at companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, Mirum Pharmaceuticals, MIRM, vesting